How to Read Your 409A Valuation Report: A Founder's Cheat Sheet

You asked for a 409A valuation, the report came back, and now you're staring at 30 pages of methodology, discount rates, and probability-weighted scenarios. The short answer is: you don't need to read all of it. But you do need to understand the parts that matter, because the numbers in this document will govern every option grant you make for the next 12 months. This guide walks through each section of a typical 409A report, tells you what to look for, and flags the questions worth asking before you sign off.

If you're still getting up to speed on what a 409A is and why you need one, the what-is-a-409a-valuation guide covers the fundamentals. And if you're unsure whether your current valuation is still valid, when should a startup get a 409A valuation walks through every timing trigger. This post picks up where those leave off: the report is in your hands, and you need to know what you're looking at.

The Structure of a 409A Report

Most 409A reports follow a consistent structure, regardless of which provider produced them. Here is what typically happens across the sections:

Section 1: The Executive Summary and FMV Conclusion

The fair market value (FMV) per share of common stock is the number the whole report is built around. It appears in the introduction and again in the conclusion. This figure becomes the minimum exercise price for any stock options you grant under this valuation. Set options below it and you risk the IRS treating those grants as non-compliant deferred compensation, which triggers a 20% additional tax on your employees.

The first thing to check: does the FMV feel reasonable given where your company is? Appraisers have an obligation to produce a number that is genuinely fair. A number that looks suspiciously low might feel like a win for option holders in the short term, but if the IRS determines the valuation is "grossly unreasonable," it can reject the report entirely and revise the tax treatment of every option issued under it. The goal is a defensible number, not the lowest possible one.

Section 2: Company Overview, Check for Factual Errors

This section describes your business: what you do, your stage, your team, your market, and your recent milestones. Appraisers gather this information through a kickoff call and the documents you provide. Read it carefully.

Errors here can quietly distort the valuation. If the report describes you as a pre-revenue company when you've been generating revenue for six months, or mischaracterizes your business model, those mistakes flow into the financial analysis and the final FMV. Before the report is finalized, you'll typically receive a draft for review. That review window is your chance to flag anything that doesn't match reality. You're not reviewing the math, you're reviewing the facts.

Section 3: Methodology, How They Got to Enterprise Value

This is the section most founders skip. You don't need to verify every calculation, but you should understand which approach was used and whether it makes sense for your stage.

For most seed and Series A companies, the Backsolve Method is the primary approach because a recent priced round provides a concrete anchor for enterprise value. If your report uses a different method, the methodology section should explain why. A DCF applied to a pre-revenue company, for example, is worth questioning, the projections driving that model carry a lot of uncertainty.

Section 4: Equity Allocation, How Value Gets Split Across Share Classes

Once the appraiser has an enterprise value, they need to figure out how much of that value belongs to common stock versus preferred stock. This is the equity allocation step, and it's where the FMV per common share actually gets calculated.

The three most common allocation methods are the Option Pricing Model (OPM), the Probability-Weighted Expected Return Method (PWERM), and the Current Value Method (CVM). The OPM treats each share class like a financial option with a different payoff structure. The PWERM models multiple exit scenarios and weights them by probability. The CVM is simpler and typically used only for companies that are very early stage or near a liquidity event.

You don't need to audit the allocation math. What you should confirm: the cap table inputs are correct (number of shares, option pool size, preferred share terms), because errors in the cap table feed directly into the allocation output.

Section 5: The DLOM, Why It Exists and What to Look For

The Discount for Lack of Marketability (DLOM) is applied after the equity allocation to reflect the fact that private company shares cannot be freely sold on an open market. Selling private shares takes time, involves legal restrictions, and requires finding a willing buyer. The DLOM reduces the allocated common stock value to account for that illiquidity.

The size of the DLOM depends on facts and circumstances specific to your company: stage, time to a likely liquidity event, and the nature of any transfer restrictions. Your report should explain the rationale for the discount applied. If it states a DLOM of, say, 25% with no explanation, that's a question worth raising with your provider.

Section 6: The Conclusion and Certification

The conclusion restates the FMV per share and includes the appraiser's certification, a formal statement that the analysis was conducted independently and in accordance with applicable standards. This is the section that establishes your IRS safe harbor protection.

Safe harbor means that if the IRS ever questions your option pricing, the burden of proof shifts to them. They would need to show that your valuation was grossly unreasonable, which is a high bar. Without a report from a qualified independent appraiser, the burden sits with you to prove your pricing was reasonable. The certification in this section is what makes the difference.

Check two things here: the effective date of the valuation (this is the date from which the 12-month validity period runs), and the appraiser's credentials. The IRS requires that the appraiser have significant knowledge, experience, education, and training in performing similar valuations. A credentialed analyst (ASA, CFA, or equivalent) signing the report is a good signal.

What to Do After You've Read the Report

Once you've reviewed the draft and confirmed the factual inputs are correct, the report is finalized. Here is what typically happens next:

1. File the final report. Store it with your corporate records. Investors will ask for it during due diligence, and your auditors will want to see it when reviewing stock-based compensation expense.
2. Record the FMV and effective date. Every option grant made under this valuation must have an exercise price at or above the FMV per share stated in the report.
3. Track the expiration. The valuation is valid for 12 months from its effective date, or until a material event occurs, whichever comes first. Set a calendar reminder at the 10-month mark so you have time to order a renewal before the window closes.
4. Watch for material events. A new funding round, a significant revenue change, or a major pivot can invalidate your current valuation before the 12 months are up. When in doubt, ask your provider whether the event qualifies as material.

A Quick Reference: Red Flags Worth Questioning

Most 409A reports from qualified providers are accurate and well-documented. But here are the situations where it's worth asking your provider a direct question:

• The effective date doesn't match when you expected the valuation to be as of, this affects your 12-month window.
• The company description contains factual errors about your revenue, stage, or business model.
• The DLOM is applied without explanation or documentation of the rationale.
• The cap table inputs don't match your actual cap table (wrong share counts, missing option pool, incorrect preferred terms).
• The methodology used doesn't fit your stage, for example, a DCF applied to a pre-revenue company with no explanation of the projection assumptions.
• The appraiser's credentials are not stated or the certification language is missing from the conclusion.

None of these automatically mean the report is wrong. But each one is a question worth asking before you finalize the report and start granting options against it. Your provider should be able to explain any of these points clearly. If they can't, that's useful information too.